Technical considerations of pharmaceutical research on recombinant poliovirus vaccine
10.13200/j.cnki.cjb.004561
- VernacularTitle:浅析重组脊髓灰质炎疫苗药学研究的技术考虑
- Author:
JIN Su
- Publication Type:Journal Article
- Keywords:
Polio;
Recombinant vaccine;
Pharmaceutical;
Virus-like particle(VLP)
- From:
Chinese Journal of Biologicals
2025;38(09):1145-1152
- CountryChina
- Language:Chinese
-
Abstract:
Recombinant poliovirus vaccines, such as virus-like particle(VLP) vaccine, may play a key role in the future Global Polio Eradication Initiative(GPEI) because of its advantages of no live virus risk and high biological safety. Compared with traditional oral poliovirus vaccine(OPV) and inactivated poliovirus vaccine(IPV), recombinant poliovirus vaccines have potential in avoiding virus leakage risk and improving thermal stability, but face new challenges in antigen design and quality control. Currently, many manufacturers have carried out related research and development, but their pharmaceutical strategies need to be optimized according to VLP characteristics. In this paper, in terms of the key points in the research and development of recombinant poliovirus vaccines, such as virus strain selection(such as wild strain. Sabin strain), antigen design(such as VP protein modification), preparation optimization(such as D antigen stability), and quality control(such as VLP granularity analysis), systematic considerations and suggestions are put forward in order to provide scientific basis for the development of the new generation vaccines, accelerate the marketing process, and help the world achieve the goal of eradicating poliomyelitis.
